These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36317680)

  • 1. Rhabdomyosarcoma xenotransplants in zebrafish embryos.
    Siebert J; Schneider M; Reuter-Schmitt D; Würtemberger J; Neubüser A; Driever W; Hettmer S; Kapp FG
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30053. PubMed ID: 36317680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
    Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
    Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma.
    Patel AG; Chen X; Huang X; Clay MR; Komorova N; Krasin MJ; Pappo A; Tillman H; Orr BA; McEvoy J; Gordon B; Blankenship K; Reilly C; Zhou X; Norrie JL; Karlstrom A; Yu J; Wodarz D; Stewart E; Dyer MA
    Dev Cell; 2022 May; 57(10):1226-1240.e8. PubMed ID: 35483358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
    Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
    Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
    Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
    J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
    Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
    Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
    Yan C; Brunson DC; Tang Q; Do D; Iftimia NA; Moore JC; Hayes MN; Welker AM; Garcia EG; Dubash TD; Hong X; Drapkin BJ; Myers DT; Phat S; Volorio A; Marvin DL; Ligorio M; Dershowitz L; McCarthy KM; Karabacak MN; Fletcher JA; Sgroi DC; Iafrate JA; Maheswaran S; Dyson NJ; Haber DA; Rawls JF; Langenau DM
    Cell; 2019 Jun; 177(7):1903-1914.e14. PubMed ID: 31031007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
    Meister MT; Groot Koerkamp MJA; de Souza T; Breunis WB; Frazer-Mendelewska E; Brok M; DeMartino J; Manders F; Calandrini C; Kerstens HHD; Janse A; Dolman MEM; Eising S; Langenberg KPS; van Tuil M; Knops RRG; van Scheltinga ST; Hiemcke-Jiwa LS; Flucke U; Merks JHM; van Noesel MM; Tops BBJ; Hehir-Kwa JY; Kemmeren P; Molenaar JJ; van de Wetering M; van Boxtel R; Drost J; Holstege FCP
    EMBO Mol Med; 2022 Oct; 14(10):e16001. PubMed ID: 35916583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of 6 pediatric rhabdomyosarcoma patient's derived xenograft models closely recapitulating patients' tumor characteristics.
    Gasparini P; Casanova M; Centonze G; Borzi C; Bergamaschi L; Collini P; Testi A; Chiaravalli S; Massimino M; Sozzi G; Ferrari A; Moro M
    Tumori; 2023 Jun; 109(3):314-323. PubMed ID: 36114629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zebrafish Rhabdomyosarcoma.
    Phelps M; Chen E
    Adv Exp Med Biol; 2016; 916():371-89. PubMed ID: 27165362
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Shoji C; Kikuchi K; Yoshida H; Miyachi M; Yagyu S; Tsuchiya K; Nakaya T; Hosoi H; Iehara T
    Oncol Rep; 2023 Apr; 49(4):. PubMed ID: 36866753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zebrafish models of rhabdomyosarcoma.
    Chen EY; Langenau DM
    Methods Cell Biol; 2011; 105():383-402. PubMed ID: 21951539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
    Pappo AS; Lyden E; Breneman J; Wiener E; Teot L; Meza J; Crist W; Vietti T
    J Clin Oncol; 2001 Jan; 19(1):213-9. PubMed ID: 11134215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
    Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
    Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric soft tissue sarcomas.
    Loeb DM; Thornton K; Shokek O
    Surg Clin North Am; 2008 Jun; 88(3):615-27, vii. PubMed ID: 18514702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
    Seitz G; Bonin M; Fuchs J; Poths S; Ruck P; Warmann SW; Armeanu-Ebinger S
    Int J Oncol; 2010 Feb; 36(2):491-500. PubMed ID: 20043085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
    Kang Z; Chen JJ; Yu Y; Li B; Sun SY; Zhang B; Cao L
    Clin Cancer Res; 2011 May; 17(10):3181-92. PubMed ID: 21385927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.